According to the data published in the National Institutes of Health (NIH) in January 2017, the most common overall cause of female infertility is the failure to ovulate, which occurs in 40% of women with infertility issues, globally. To treat such infertility problems in females, clomiphene citrate is the first choice of medicine for the past 40 years, according to the Global Library of Women’s Medicine. Gynecologists prescribe clomiphene for 1 to 6 months or more with a low dose of 50 mg daily (1 tablet) for 5 days. If ovulation does not occur after the first course of therapy, a second course of 100 mg daily (two 50 mg tablets given as a single daily dose) for 5 days is prescribed.
According to a study called ‘Clomiphene citrate usage pattern in India' conducted by Fertility Science and Research in 2014, ovulation rate was reported to increase from 21% to 60% and the pregnancy rate was noticed to be increased by 11% to 30% by majority of participants. The ovulation rate and pregnancy rate was increased using clomiphene citrate because of increased secretion of hypothalamic gonadotropin-releasing hormone (GnRH) to increase the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which will, in turn, stimulate ovarian follicular activity.
Market Dynamics
High incidence of polycystic ovarian syndrome is expected to be a key driver for the clomiphene citrate market growth. For instance, according to an article published in 2014 in Clinical Epidemiology, polycystic ovarian syndrome affects 8% to 20% of the reproductive-age women, globally. According to the World Health Organization, in 2012, polycystic ovarian syndrome affected 116 million women, worldwide.
The clomiphene citrate market growth is hindered by side effects shown by this drug, which includes headache, nausea, upper respiratory tract infection, abdominal tenderness, sinus congestion, mood swings, acne, breast tenderness, weight gain, pelvic discomfort, abnormal bleeding or spotting, vomiting, injection site pain, redness, dizziness, and ovarian hyper-stimulation syndrome (OHSS). For instance, according to a study published in NCBI, in 2016, 10% to 20% of women who consumed clomiphene citrate developed a mild form of OHSS, which will usually resolve on its own. Severe cases of OHSS occurred in less than one percent of patients in the U.S.
Key features of the study
• This report provides in-depth analysis of the global clomiphene citrate market, market size (USD Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2026-2033, considering 2025 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global clomiphene citrate market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include Sanofi S.A., Par Pharmaceutical, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Cipla Inc., Unichem Laboratories Ltd., Emcure Pharmaceuticals Ltd., Serum Institute of India Pvt. Ltd., Incepta Pharmaceuticals Ltd., and Shanghai Trifecta Pharma Co. Ltd.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global clomiphene citrate market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for clomiphene citrate market, research and consulting firms, new entrants, and financial analysts
Clomiphene Citrate Market Segmentation
• By Indication
o PCOS
o Secondary Amenorrhea
o Psychogenic Amenorrhea
o Amenorrhea Galactorrhea Syndrome
o Others
• By Distribution Channel
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Global Clomiphene Citrate Market, By Region
o North America
 U.S.
 Canada
o Latin America
 Brazil
 Mexico
 Argentina
 Rest of Latin America
o Europe
 Germany
 U.K.
 France
 Italy
 Spain
 Russia
 Rest of Europe
o Asia Pacific
 China
 India
 Japan
 Australia
 South Korea
 ASEAN
 Rest of Asia Pacific
o Middle East
 GCC
 Israel
 Rest of Middle East
o Africa
 South Africa
 Central Africa
 North Africa
• Key Players
o Sanofi S.A
o Par Pharmaceutical
o Merck & Co. Inc
o Teva Pharmaceutical Industries Ltd
o Cipla Inc
o Unichem Laboratories Ltd
o Emcure Pharmaceuticals Ltd
o Serum Institute of India Pvt. Ltd
o Incepta Pharmaceuticals Ltd
o Shanghai Trifecta Pharma Co. Ltd

Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Overview
o Report Description
 Market Definition and Scope
o Executive Summary
 Global Clomiphene Citrate Market, By Indication
 Global Clomiphene Citrate Market, By Distribution Channel
 Global Clomiphene Citrate Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Impact Analysis
o Key Highlights
o Regulatory Scenario
o Product Launches/Approvals
o PEST Analysis
o PORTER’s Analysis
o Market Opportunities
o Regulatory Scenario
o Key Developments
o Industry Trend
4. Global Clomiphene Citrate Market, By Indication, 2021-2033, (USD Mn)
o Introduction
 Market Share Analysis, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, 2022 - 2033
 Segment Trends
o PCOS
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Secondary Amenorrhea
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Psychogenic Amenorrhea
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Amenorrhea Galactorrhea Syndrome
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Others
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Clomiphene Citrate Market, By Distribution Channel, 2021-2033, (USD Mn)
o Introduction
 Market Share Analysis, 2026 and 2033 (%)
 Y-o-Y Growth Analysis, 2022 - 2033
 Segment Trends
o Hospital Pharmacies
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Retail Pharmacies
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Online Pharmacies
 Introduction
 Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Clomiphene Citrate Market, By Region, 2021 - 2033, Value (USD Mn)
o Introduction
 Market Share (%) Analysis, 2026 & 2033, Value (USD Mn)
 Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
 Regional Trends
o North America
 Introduction
 Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
 Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
 Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
o U.S.
o Canada
o Latin America
 Introduction
 Value (USD Mn)
 Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
 Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
 Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
o Brazil
o Argentina
o Mexico
o Rest of Latin America
o Europe
 Introduction
 Value (USD Mn)
 Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
 Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
 Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
o Germany
o U.K.
o Spain
o France
o Italy
o Russia
o Rest of Europe
o Asia Pacific
 Introduction
 Value (USD Mn)
 Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
 Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
 Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
 Introduction
 Value (USD Mn)
 Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
 Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
 Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
o GCC Countries
o Israel
o Rest of Middle East
o Africa
 Introduction
 Value (USD Mn)
 Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
 Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
 Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
o South Africa
o North Africa
o Central Africa
7. Competitive Landscape
o Sanofi S.A.
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Par Pharmaceutical
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Merck & Co. Inc.
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Teva Pharmaceutical Industries Ltd.
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Cipla Inc.
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Unichem Laboratories Ltd.
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Emcure Pharmaceuticals Ltd.
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Serum Institute of India Pvt. Ltd.
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Incepta Pharmaceuticals Ltd.
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
o Shanghai Trifecta Pharma Co. Ltd.
 Company Highlights
 Product Portfolio
 Key Developments
 Financial Performance
 Strategies
8. Analyst Recommendations
o Wheel of Fortune
o Analyst View
o Coherent Opportunity Map
9. References and Research Methodology
o References
o Research Methodology
o About us